HGHasan Göze

Hasan Göze

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hasan Göze has a total of 75 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Diagnostic and Prognostic Value of Platelet Indices in Acute Ischemic Stroke: A Retrospective Analysis

    by Hasan Göze, Yasin Koçak, Erdinç Şengüldür

    Objective: Platelet indices are routinely available, but their diagnostic value in patients with stroke-suggestive symptoms remains uncertain. This study evaluated the diagnostic and prognostic performance of these indices in an emergency department population. Methods: This retrospective study included adults who underwent neurology consultation between June 1, 2023, and June 1, 2026. Eligible patients had stroke-suggestive symptoms, relevant neuroimaging, and complete blood count data. Patients were classified as having acute ischemic stroke (AIS), transient ischemic attack (TIA), or nonstroke presentation. Platelet count, mean platelet volume (MPV), plateletcrit, platelet distribution width, and their derived ratios were analyzed. Diagnostic performance was assessed using receiver operating characteristic curve analysis and logistic regression. Thirty-day mortality was evaluated among patients with ischemic cerebrovascular events. Results: Of 4218 screened patients, 1079 were included: 799 nonstroke, 256 AIS, and 24 TIA. None of the platelet parameters differed significantly between the nonstroke and combined stroke/TIA groups. Area under the curve (AUC) values ranged from 0.50 to 0.51. None of the parameters remained significantly associated with ischemic cerebrovascular events after adjustment for age, sex, hypertension, diabetes mellitus, and previous stroke. MPV was lower in 30-day nonsurvivors than in survivors (median [IQR], 10.6 [9.7-11.1] fL vs 11.1 [10.3-11.8] fL; P = .049); however, this association was based on univariable analysis only because the limited number of mortality events (n = 16) precluded reliable multivariable analysis. Conclusions: Platelet parameters did not provide clinically meaningful diagnostic discrimination between ischemic cerebrovascular events and nonstroke presentations. The isolated association between lower MPV and 30-day mortality was exploratory and should be interpreted cautiously.

  • Open Access

    Integrated Prognostic Modelling with the CALLY Index and Interim PET/CT in Hodgkin Lymphoma

    by Hasan Göze, İsmail Eren Polat, Nermin Bal, İsa Yalçınkaya, Gokhan Burul, Büşra Tuğçe Tonyalı, Tahir Alper Cinli, İstemi Serin

    Background/Objectives: Interim 18F-FDG PET/CT is the most powerful prognostic tool in Hodgkin lymphoma but is only available after 2 cycles and does not guide initial treatment. The C-reactive protein-albumin-lymphocyte (CALLY) index is a novel composite index of inflammation, nutrition, and immunity, measurable at diagnosis, but has not been studied in Hodgkin lymphoma (HL). We tested whether baseline CALLY could predict interim PET response and survival and whether combining the two provides additional information over either alone. Methods: A retrospective study of 180 consecutive patients with newly diagnosed Hodgkin lymphoma at a single center was performed. CALLY was defined as albumin (g/L) × lymphocytes (×109/L)/CRP (mg/L). Interim PET after two cycles was scored using the Deauville scale (4–5 positive). The endpoints were progression-free survival (PFS) and overall survival (OS). Results: Median follow-up was 30.5 months, 32 patients had a PFS event, and 16 died. Interim PET was positive in 31/163 patients (19.0%). Baseline CALLY was lower in PET-positive patients compared with PET-negative patients (median 1.16 vs. 3.34; p = 0.022; area under the curve 0.635, modest discrimination). Interim PET positivity (29.8% vs. 13.0%; OR 2.84, 95% CI 1.26–6.42), 24-month PFS (66.9% vs. 89.8%; p = 0.001) and OS (84.8% vs. 95.5%; p = 0.022) were reduced below a Youden-derived threshold of 1.5. CALLY was not independently prognostic after adjustment for interim PET (PFS hazard ratio [HR] 1.86, 95% CI 0.79–4.37; p = 0.157). A three-tier exploratory model combining both factors separated 24-month PFS into 94.5% (n = 87), 79.6% (n = 53), and 41.2% (n = 17) (p < 0.001; high- vs. low-risk HR 9.48, 95% CI 3.59–25.04), although the intermediate tier was not statistically different from the low-risk tier. Conclusions: In this cohort, baseline CALLY provides a low-cost pre-treatment correlate of early metabolic response and outcome, with numerically greater discrimination than the International Prognostic Score. Its prognostic signal seems largely mediated through the interim PET response, and therefore it should complement, not replace, interim response assessment. Discrimination was modest, and the integrated model is exploratory and requires prospective multicenter validation in contemporary protocols before clinical use.

  • Open Access

    Beyond conventional genetics: impact of next-generation sequencing integration in acute myeloid leukemia

    by Hasan Göze, Tuna Eren Esen, İsa Yalçınkaya, Gökhan Burul, Tahir Alper Cinli, Mesut Ayer, İstemi Serin

    Aim: To determine whether next-generation sequencing (NGS) improves 2022 European LeukemiaNet (ELN) risk stratification by identifying myelodysplasia-related (MDS-related) mutations in acute myeloid leukemia (AML). Methods: We analyzed 111 consecutive adults with newly diagnosed non-promyelocytic acute myeloid leukemia (AML) who underwent diagnostic NGS with a myeloid gene panel. For each patient, an ELN 2022 risk category was assigned using four diagnostic modalities—metaphase karyotyping, fluorescence in situ hybridization (FISH), targeted molecular (PCR) testing, and NGS. A conventional category was defined as the most adverse assignment obtained from karyotyping, FISH, and PCR, whereas the NGS-inclusive category was defined as the most adverse assignment obtained when NGS was added to these modalities. The primary outcome was within-patient reclassification attributable to the incorporation of NGS. Reporting followed the STROBE guidelines. Results: The median age was 56 years, and 65.8% of patients were male. The most frequently mutated genes were FLT3 (25.2%), NPM1 (19.8%), TET2 (17.1%), TP53 (16.2%), and RUNX1 (16.2%); 38.7% of patients harbored at least one MDS-related mutation. Among the 110 patients with both classifications available, incorporation of NGS upgraded the ELN 2022 category in 33 patients (30.0%; 95% CI, 22.2–39.1)—29 from intermediate and 4 from favorable to adverse—with no downgrades. The proportion of patients classified as adverse risk more than doubled, from 30 (27.3%) to 63 (57.3%) (McNemar p < 0.001). Upgrades were driven predominantly by MDS-related mutations: 29 of 33 upgraded patients (87.9%) carried at least one such mutation, most commonly in ASXL1 (45.5%), RUNX1 (39.4%), SRSF2 (30.3%), or STAG2 (24.2%). Conclusions: Even among patients selected for NGS testing, an ELN 2022 category based on conventional cytogenetic and PCR testing alone was inaccurate, almost invariably too favorable, in approximately one in three patients, and no clinical feature reliably identified them. NGS is therefore indispensable for accurate risk stratification in AML.

  • Open Access

    Is Baseline PET/CT-Derived Metabolic Tumor Burden Associated with Treatment Response and Survival in Hodgkin Lymphoma?

    by Büşra Tuğçe Tonyalı, Mehmet Günhan Tekin, Sefa Bayram, Selin Gül Yaran, Gökhan Burul, Edibe Sevde Eker, Tahir Alper Cinli, Hasan Göze, Burcu Esen Akkaş, Mesut Ayer

    Background/Objectives: Metabolic tumor volume (MTV) and total lesion glycolysis (TLG) provide quantitative assessments of metabolically active tumor burden; however, their prognostic value in Hodgkin lymphoma (HL) remains uncertain. This study evaluated the associations of baseline PET/CT-derived MTV and TLG with clinical disease characteristics, treatment response, progression-free survival (PFS), and overall survival (OS) in patients with classical HL. Methods: This retrospective single-center study included 105 adults diagnosed with classical HL between July 2020 and April 2023. Baseline PET/CT images were analyzed using LIFEx 7.1.0. Volumes of interest were delineated using a fixed threshold of 41% of SUVmax. Total MTV and TLG were calculated by summing the values of all FDG-avid lesions. Survival outcomes were evaluated using Kaplan–Meier analysis, the log-rank test, and Cox proportional hazards regression. Results: The median age was 33 years, and the median follow-up was 24 months. Higher MTV and TLG were significantly associated with advanced-stage disease, high International Prognostic Score, B symptoms, bulky disease, and extranodal involvement. Higher MTV was associated with a lower end-of-treatment response rate, whereas higher TLG was associated with lower interim and end-of-treatment response rates. Disease progression occurred in 19 patients, and 11 patients died. Compared with patients with MTV < 249, those with MTV ≥ 249 had numerically higher hazards of progression (HR = 2.18, 95% CI: 0.88–5.40; p = 0.09) and death (HR = 1.21, 95% CI: 0.37–3.96; p = 0.75). Compared with patients with TLG < 1252, those with TLG ≥ 1252 had a numerically higher hazard of progression (HR = 1.53, 95% CI: 0.61–3.86; p = 0.37) but a lower hazard of death (HR = 0.56, 95% CI: 0.17–1.85; p = 0.34). However, all confidence intervals included 1, and none of these differences reached statistical significance. Conclusions: Baseline MTV and TLG reflect disease burden and are associated with treatment response in classical HL. However, neither parameter was significantly associated with PFS or OS in this cohort. Their potential value as survival prognostic biomarkers requires confirmation in larger prospective studies with longer follow-up.

  • Monocyte-Derived Chemokines in Immune Thrombocytopenia: Diagnostic and Pathogenic Insights from a Cross-Sectional Case-Control Study

    by Hasan Göze, Ahmet Muzaffer Demir

    Aim: Immune thrombocytopenia (ITP) is an autoimmune disorder with incompletely understood immunopathogenesis. This study aimed to evaluate the serum levels of monocyte-derived chemokines—CCL1, CCL3, CCL4, and CCL16—in newly diagnosed ITP patients, with a focus on their potential diagnostic and pathogenic relevance.Material and Methods: In a cross-sectional case-control design, 84 patients with primary ITP and 84 age- and sex-matched healthy controls were included. Serum chemokine concentrations were measured using ELISA.Results: CCL4 levels were significantly elevated in ITP patients (p < 0.001) and emerged as an independent predictor (OR = 1.158, p = 0.005). CCL1 levels were moderately increased (p = 0.038), and CCL3 reached statistical significance after outlier correction (p = 0.015). No significant differences were observed for CCL16. The logistic regression model yielded an overall classification accuracy of 82.1%, with ROC analysis supporting the potential diagnostic utility of CCL4.Conclusion: CCL4 may serve as a useful biomarker in the diagnosis and immunological assessment of ITP. Although CCL1 and CCL3 also showed some associations with disease status, further research is needed to clarify their clinical significance. Chemokine profiling may enhance the understanding of ITP’s immune mechanisms and support clinical monitoring strategies.

  • Open Access

    Baseline Clinical and Laboratory Predictors of Treatment Requirement in Chronic Lymphocytic Leukemia: A Retrospective Cohort Study Using Hierarchical Modeling

    by Hasan Göze, Birgül Öneç

    Background/Objectives: Chronic lymphocytic leukemia (CLL) is characterized by a highly heterogeneous clinical course, with some patients remaining stable for years while others require early treatment. Identifying reliable and easily accessible predictors of treatment requirement at diagnosis remains an important clinical challenge. Methods: This retrospective cohort study included 226 patients diagnosed with CLL between 2015 and 2024 at a tertiary care center. Baseline demographic, clinical, and laboratory parameters were analyzed. Univariate and multivariable logistic regression analyses were performed to identify independent predictors of treatment requirement. A hierarchical mixed-effects model was constructed to account for temporal clustering across diagnostic periods. A clinical risk score was derived from independent predictors, using regression coefficient-based weighting, and its discriminative performance was evaluated using receiver operating characteristic (ROC) analysis. Results: A total of 226 patients were included (mean age: 62.4 ± 13.8 years; 56.6% male). During follow-up, 104 patients (46.0%) required treatment. Lower hemoglobin and platelet levels, higher lymphocyte counts and LDH levels, and the presence of B symptoms, splenomegaly, and advanced disease stage were independently associated with treatment requirement. These associations remained significant in hierarchical modeling. The derived risk score demonstrated acceptable discriminative ability (AUC: 0.84; 95% CI: 0.79–0.89), with a cut-off value of ≥4 yielding a sensitivity of 81.7% and specificity of 73.8%. Conclusions: Baseline clinical and laboratory parameters are associated with treatment requirement in CLL. A combination of readily available variables may support risk stratification at diagnosis. The proposed risk score may provide a practical adjunct to routine clinical assessment, particularly in settings where advanced molecular testing is not readily available; however, external validation in independent cohorts is required before clinical implementation.

  • Open Access

    Comparative Prognostic Performance of Nutritional and Inflammatory Indices in Diffuse Large B-Cell Lymphoma

    by Tahir Alper Cinli, Gökhan Burul, Hasan Göze, Mesut Ayer, Istemi Serin

    Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma. Despite advances in immunochemotherapy, approximately 30–40% of patients experience relapsed or refractory disease. Nutritional and inflammatory status, reflected by composite indices, may independently influence clinical outcomes. However, the prognostic value of the Prognostic Nutritional Index (PNI), Geriatric Nutritional Risk Index (GNRI), and Hemoglobin-Albumin-Lymphocyte-Platelet (HALP) score has not been well established in DLBCL patients treated with rituximab-based regimens. Methods: We retrospectively analyzed 192 patients with newly diagnosed DLBCL who received at least three cycles of R-CHOP or R-EPOCH at Başakşehir Çam and Sakura City Hospital between January 2020 and January 2026. Receiver operating characteristic (ROC) curve analysis was performed to determine optimal cutoff values. Kaplan–Meier analysis with log-rank testing and univariable/multivariable Cox proportional hazards regression analyses were used to evaluate the prognostic impact of the PNI, GNRI, and HALP on overall survival (OS) and progression-free survival (PFS). Results: Among the six indices evaluated (PNI, GNRI, HALP, SII, ALI, and CAR), the PNI demonstrated the highest discriminatory ability for OS (AUC = 0.734, p = 0.001), followed by the HALP (AUC = 0.671, p = 0.020) and GNRI (AUC = 0.668, p = 0.022). The optimal cutoff values were ≤46.45 for the PNI, ≤46.91 for the GNRI, and ≤223.95 for HALP. Low values of all three indices were significantly associated with elevated LDH levels, advanced Ann Arbor stage, and higher IPI category. Kaplan–Meier analysis demonstrated significantly inferior OS in the low PNI (52.8 ± 2.6 vs. 67.1 ± 1.2 months, p = 0.001), low GNRI (49.5 ± 3.1 vs. 66.0 ± 1.4 months, p = 0.001), and low HALP (58.8 ± 2.8 vs. 64.9 ± 1.2 months, p = 0.005) groups. In separate multivariable Cox models adjusted for sex and IPI, the PNI (HR = 0.216, p = 0.009), HALP (HR = 0.276, p = 0.031), and GNRI (HR = 0.294, p = 0.011) remained independently associated with OS. No significant association was observed between these indices and PFS. Conclusions: The PNI, GNRI, and HALP are independent prognostic markers in patients with DLBCL treated with rituximab-based regimens. These readily available and inexpensive baseline indices may complement the IPI in identifying patients at higher risk of adverse outcomes and support risk stratification at diagnosis.

  • Open Access

    Prognostic Value of Serial Lactate Dehydrogenase Measurements for Determining Early Mortality in ICU Patients: A Retrospective Cohort Study

    by Hasan Göze, Türkay Akbaş

    Background: This study investigated whether lactate dehydrogenase (LDH) levels measured at ICU admission predict early in-hospital mortality among critically ill medical patients in a single-center retrospective cohort study conducted in Turkey. Specifically, we aimed to (i) determine an optimal LDH threshold; (ii) examine the temporal trajectory of discriminatory performance over 72 h; and (iii) assess LDH as an independent predictor beyond established severity scores. Methods: In this single-center retrospective cohort study, 681 adults admitted to a medical ICU between January 2015 and January 2025 were analyzed. Serial LDH measurements were obtained at 0, 24, 48, and 72 h after ICU admission. This study was approved by the Institutional Ethics Committee (Decision No.: 2025/99). ROC analysis was performed under a predefined sensitivity constraint (≥0.70), and time-to-event outcomes were examined using Kaplan–Meier methods and Cox proportional hazards regression. Determinants of maximum LDH were assessed using a GLM with Gamma distribution and log link. Results: The 28-day mortality rate was 39.1%. ROC analysis identified an optimal 24-h LDH cut-off of approximately 275 U/L (AUC = 0.650; sensitivity = 0.70). Discriminatory performance improved progressively over time (AUC of 0.632 at baseline to 0.690 at 72 h), suggesting that serial measurements may capture evolving prognostic information more effectively than single-time-point measurements. Kaplan–Meier analyses demonstrated a stepwise decline in survival with increasing LDH across all categorization approaches (all log-rank p < 0.001). In multivariable Cox models, log-transformed maximum LDH within the first 72 h was the strongest independent predictor of mortality (HR = 2.2–2.6; p < 0.001), demonstrating larger effect sizes than APACHE II, SOFA, and age in fully adjusted models. GLM analysis indicated that male sex was associated with approximately 33% lower expected maximum LDH. Conclusions: Admission LDH is an independently predictive and readily obtainable prognostic biomarker for early in-hospital mortality in critically ill medical patients. LDH may complement established ICU risk assessment tools, and its integration into clinical workflows as a triage adjunct warrants further evaluation in prospective multicenter studies.

  • Open Access

    Diagnostic Value of Platelet Indices in Pulmonary Thromboembolism: A Retrospective Analysis

    by Hasan Göze, Erdinç Şengüldür

    Background: Timely and accurate diagnosis of pulmonary thromboembolism (PTE) in the emergency department (ED) is critical, yet remains challenging due to non-specific clinical features. Platelet indices have recently emerged as potential biomarkers, but their diagnostic utility is uncertain. Methods: In this retrospective single-center study, 1198 adult patients who underwent CT pulmonary angiography for suspected PTE in a tertiary ED were analyzed. Demographic characteristics and a comprehensive panel of hematological, biochemical, and coagulation parameters were compared between PTE (n = 126) and non-PTE (n = 1072) groups. Multivariate logistic regression and ROC curve analyses were performed to assess independent predictors and diagnostic performance. Results: Platelet indices including platelet count, mean platelet volume, platelet distribution width, plateletcrit, and derived ratios showed no significant differences between groups. However, PTE patients were older, more likely female, and exhibited significantly lower red blood cell count, hemoglobin, hematocrit, and higher neutrophil count (all P < .05). Multivariate analysis identified lower RBC and higher neutrophil count as independent predictors, while female sex was associated with decreased PTE risk. The model's discriminative ability was modest (AUC = 0.651). Conclusion: Platelet indices do not provide diagnostic value for PTE in the ED. Traditional demographic and hematological markers may aid risk stratification, but clinical integration remains essential. Prospective studies are needed to validate these findings and enhance diagnostic pathways.


  • Open Access

    Kronik Lenfositik Lösemi

    by Selin Merih Urlu, Sedanur Karaman Gülsaran, Sinan Demircioğlu, Hakan Keski, Esma Evrim Doğan, Rafet Eren, Gülten Korkmaz Akat, Emrah Kılıçaslan, Nazlı Demir, Sude Hatun Aktimur, et al.

    Bu üründe yer alan bilgiler sadece lisanslı tıbbi